IGHE and food allergy: In February 2024, the Food and Drug Administration (FDA) approved omalizumab for reducing allergic reactions, including anaphylaxis, resulting from accidental exposure to one or more foods in individuals ≥ 1 year of age with IgE-mediated food allergies [66].